HHS & Healthcare Contracts Intelligence — June 25, 2026

Leidos Holdings subsidiary secured a one-year, $63.1M cost-plus-fixed-fee delivery order from NIH/NCI for R&D facility operations, with a base-plus-options value of $67.1M. The cost-plus structure limits upside but reduces execution risk, and the short performance period suggests steady, non-transformative revenue.

The contract is cost-plus-fixed-fee, which typically yields lower margins (6-9%) compared to fixed-price contracts, limiting profit upside for Leidos.

Full and open competition with no set-aside means Leidos won on merit, but competitors could bid on future similar contracts, increasing competitive pressure.

This single contract represents a modest portion of Leidos' overall revenue ($63.1M vs. Leidos' ~$15B annual revenue), so it is not a concentration risk for the company.

NIH NCI's consistent funding for cancer research creates opportunities for Leidos to secure follow-on awards or option exercises for similar facility operations contracts.

This $63.1M award to Leidos underscores the NIH's ongoing investment in cancer research infrastructure, a historically stable funding area within civilian agencies.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"This $63.1M contract is a small, neutral signal for Leidos, but its one-year duration and cost-plus structure limit impact. Watch for option exercise or follow-on awards to gauge NIH NCI relationship strength.", "trigger"=>"Contract end date: 2020-08-30; monitor for option exercise or re-compete announcements from NIH NCI"}